Elevation Accounts Payable vs Common Stock Analysis
ELEV Stock | USD 0.61 0.03 5.17% |
Elevation Oncology financial indicator trend analysis is much more than just examining Elevation Oncology latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Elevation Oncology is a good investment. Please check the relationship between Elevation Oncology Accounts Payable and its Common Stock accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.
Accounts Payable vs Common Stock
Accounts Payable vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Elevation Oncology Accounts Payable account and Common Stock. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Elevation Oncology's Accounts Payable and Common Stock is -0.18. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock in the same time period over historical financial statements of Elevation Oncology, assuming nothing else is changed. The correlation between historical values of Elevation Oncology's Accounts Payable and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Elevation Oncology are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Accounts Payable i.e., Elevation Oncology's Accounts Payable and Common Stock go up and down completely randomly.
Correlation Coefficient | -0.18 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents Elevation Oncology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Elevation Oncology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Common Stock
Most indicators from Elevation Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Elevation Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.At this time, Elevation Oncology's Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 0.02 in 2024, whereas Tax Provision is likely to drop slightly above 26 K in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 18K | 27K | 39K | 27.2K | Cost Of Revenue | 18K | 27K | 39K | 27.2K |
Elevation Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Elevation Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.